← brief for 2026-09-16 · Slowing decline

Twelve-month real-world outcomes of sparsentan in a multicenter Spanish IgA nephropathy cohort.

Article C Peer reviewed Observational

Key takeaways

Doctors across several centers in Spain looked back at records of people with IgA nephropathy who took sparsentan in everyday care. IgA nephropathy is a kidney disease caused by immune deposits. Sparsentan is a drug that lowers protein in the urine. The study checked whether the drop in urine protein seen in trials lasted a full 12 months outside a trial. It is observational and looks back in time, so it shows what happened, not proof the drug caused it. The part of the paper we have does not give how many people took part or how much protein fell.

Who did this work

García-Carro C · Rodríguez-Moreno A · Cordero L · Pérez-Gómez MV · Rusiñol HM · Pasache E · Morales A · Zamora R · Parra D · Villa J · Guillén-Olmos E · Coll-Brito V

Source

Article · PubMed, the drug frontier · 2026 Sep 1
https://pubmed.ncbi.nlm.nih.gov/42746507/